QuantumScape shares fell 7% Monday to $4.56 after touching a new 52-week low of $4.54, extending year-to-date losses to approximately 56%. The decline came without a fresh company announcement or other specific corporate catalyst, as investors focus on the long timeline before commercial-scale manufacturing. Trading volume was about 7 million shares, well below the typical daily volume of nearly 19 million. TD Cowen cut its price objective to $6 from $8 in July while retaining a Hold recommendation. Five research firms rate the shares Hold and one rates them Sell, producing a consensus Reduce rating and an average price target of about $9.47. QuantumScape reported a second-quarter net loss of $98.2 million and expects adjusted EBITDA losses of $250 million to $275 million in 2026. It ended the quarter with $859 million in liquidity and lowered its 2026 capital-expenditure guidance to $27 million-$37 million. The company revised its partnership with Volkswagen’s PowerCo in July, reducing milestone payment commitments from about $131 million to $75 million, while saying lower project costs should offset the change. Second-quarter billings reached $10.8 million, taking first-half billings to $21.8 million, above the $19.5 million recorded in all of 2025. Management plans to double Eagle Line cell production in the second half of 2026 and continues to target commercial manufacturing with PowerCo in 2029. Honda entered a multiyear research partnership with QuantumScape in June, and the company has relationships with two other major automakers, including test-cell deliveries to one additional carmaker. Insiders sold 321,644 shares worth approximately $2 million over the past 90 days and made no purchases during the recent weakness, while some institutional investors increased their holdings.